Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Total Liabilities (2016 - 2026)

Angiodynamics' Total Liabilities history spans 16 years, with the latest figure at $87.3 million for Q1 2026.

  • For Q1 2026, Total Liabilities fell 12.28% year-over-year to $87.3 million; the TTM value through Feb 2026 reached $87.3 million, down 12.28%, while the annual FY2025 figure was $97.2 million, 13.3% down from the prior year.
  • Total Liabilities reached $87.3 million in Q1 2026 per ANGO's latest filing, down from $93.3 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $154.3 million in Q2 2023 to a low of $66.1 million in Q3 2023.
  • Average Total Liabilities over 5 years is $110.8 million, with a median of $104.8 million recorded in 2024.
  • Peak YoY movement for Total Liabilities: crashed 53.94% in 2023, then soared 46.72% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $150.2 million in 2022, then tumbled by 34.51% to $98.4 million in 2023, then increased by 6.49% to $104.8 million in 2024, then fell by 10.91% to $93.3 million in 2025, then decreased by 6.46% to $87.3 million in 2026.
  • Per Business Quant, the three most recent readings for ANGO's Total Liabilities are $87.3 million (Q1 2026), $93.3 million (Q4 2025), and $86.8 million (Q3 2025).